Dr. Reddy’s Laboratories has entered into a license agreement with Shanghai Henlius Biotech, Inc related to the development and commercialization of HLX15, Henlius’ investigational daratumumab biosimilar candidate to Darzalex and Darzalex Faspro. HLX15 is a recombinant anti-CD38 fully human monoclonal antibody injection, with intravenous as well as subcutaneous formulations, that is being developed as a biosimilar for the treatment of multiple myeloma.